European Autoimmune Disease Diagnostics MarketFrost & SullivanOctober 15, 2008 95 Pages - SKU: MC2013990 |
|
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
4/30/2012 | published by: GBI Research
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments Summary GBI Research, the leading business intelligence provider, has released its latest
|
more...
|
$3,500.00
|
|
Celiac Disease - Pipeline Assessment and Market Forecasts to 2019
12/5/2011 | published by: GlobalData
Celiac Disease - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, “Celiac Disease - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source
|
more...
|
$3,500.00
|
|
Liver Disease Treatments: The Global Market
1/1/2012 | published by: BCC Research
In 2009, the global market for drugs used to treat liver disease was worth approximately $12.4 billion. Sales in 2010 decreased and the market did not see much progress, causing overall global sales to remain
|
more...
|
$4,850.00
|
|
Systemic Lupus Erythematosus – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
Systemic Lupus Erythematosus – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Systemic Lupus Erythematosus - Pipeline Review, H1 2012', provides an overview of the Systemic Lupus Erythematosus therapeutic pipeline. This report provides information on the therapeutic
|
more...
|
$500.00
|
|
Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market
12/1/2011 | published by: GBI Research
Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market Summary GBI Research, the leading business intelligence provider, has released its latest research “Monoclonal
|
more...
|
$3,500.00
|
|
Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success
2/14/2012 | published by: GBI Research
Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success Summary GBI Research, the leading business intelligence provider, has released its latest research, “Endpoints - Clinical Trials
|
more...
|
$3,500.00
|
|
Psoriasis – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
Psoriasis – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Psoriasis - Pipeline Review, H1 2012', provides an overview of the Psoriasis therapeutic pipeline. This report provides information on the therapeutic development for Psoriasis, complete with latest
|
more...
|
$500.00
|
|
Use of Biomarkers to Predict Response to Biologics Therapy in Autoimmune Diseases
6/1/2011 | published by: Decision Resources
Despite ongoing research in drug safety and efficacy, even physicians agree that the ability to predict response to high-priced autoimmune biologics is a largely untapped field. Biomarkers are the ideal vehicles to elucidate information about
|
more...
|
$4,600.00
|
|
Chronic Plaque Psoriasis Global Clinical Trials Review, Q2, 2011
6/24/2011 | published by: GlobalData
Chronic Plaque Psoriasis Global Clinical Trials Review, Q2, 2011 Summary GlobalData's clinical trial report, “Chronic Plaque Psoriasis Global Clinical Trials Review, Q2, 2011 provides data on the Chronic Plaque Psoriasis clinical trial scenario. This report provides elemental
|
more...
|
$1,000.00
|
|
Product Profiles: Systemic Lupus Erythematosus - Benlysta approval brings lessons and hope to market
6/27/2011 | published by: Datamonitor
Introduction Datamonitor surveyed 108 rheumatologists in the US in the wake of Benlysta’s approval, gauging current perceptions of the drug and the clinical impact that it will have. Lessons learned from the clinical trial
|
more...
|
$11,400.00
|
Related Markets
Autoimmune Reports
- Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
- Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success
- Liver Disease Treatments: The Global Market
- Celiac Disease - Pipeline Assessment and Market Forecasts to 2019
- Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market
